Get the Stockscreener App
47.67
3.66%
-1.81
Scholar Rock Holding Corp stock is traded at $47.67, with a volume of 838.70K.
It is down -3.66% in the last 24 hours and down -8.91% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$49.48
Open:
$49.71
24h Volume:
838.70K
Relative Volume:
0.61
Market Cap:
$5.71B
Revenue:
$47.30M
Net Income/Loss:
$-408.73M
P/E Ratio:
-13.29
EPS:
-3.5865
Net Cash Flow:
$-303.86M
1W Performance:
-9.82%
1M Performance:
-8.91%
6M Performance:
+7.63%
1Y Performance:
+21.89%
1-Day Range:
$47.54
$49.95
1-Week Range:
$47.27
$53.33
52-Week Range:
$27.07
$58.49
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
47.67 | 5.71B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK|Scholar Rock Holding Corp|Price:47.670|Chg%:-1.810 - TradingKey
ETFs Investing in Scholar Rock Holding Corp. Stocks - TradingView
D.A. Davidson & CO. Purchases New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
SRRK Reiterated by Wedbush -- Price Target Maintained at $58 - GuruFocus
Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026 - Reuters
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Law firm investigates Scholar Rock officers for possible shareholder duty breaches - Pluang
Scholar Rock awaits FDA decision on apitegromab EU approval - Investing.com
SMA treatment review in Europe awaits FDA facility classification - Stock Titan
Jennison Associates LLC Buys 545,304 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
11 New Hires Get Scholar Rock Equity Awards Covering 118,586 Shares - Stock Titan
Scholar Rock (SRRK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Scholar Rock (SRRK) Q3 2025 earnings summary - Quartr
Scholar Rock schedules Aug. 6 webcast before markets open - Stock Titan
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Scholar Rock Holding Corporation $SRRK Holdings Raised by Candriam S.C.A. - MarketBeat
SRRK Stock Prediction: Huge SMA Drug Launch Breakthrough? (2026 Alert) Marcus Smart (7wRYet6o9c) - Mshale
Scholar Rock Holding (SRRK) Rallies As Pipeline Story Meets A Fair Value Question - simplywall.st
SG Americas Securities LLC Cuts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (SRRK) Q1 2025 earnings summary - Quartr
Inside THNR: A Leaner Approach to Weight Loss Investing - ETF Database
Scholar Rock stock hits 52-week high at 56.56 USD By Investing.com - Investing.com Canada
Scholar Rock stock hits 52-week high at 56.56 USD - Investing.com
Form 144 Scholar Rock Holding Corp. For: 6 July By Investing.com - Investing.com Canada
Scholar Rock (NASDAQ: SRRK) director 10b5-1 sale of 3,053 shares - Stock Titan
Scholar Rock (SRRK) director’s 3,053-share sale tied to RSU tax obligations - Stock Titan
Scholar Rock (SRRK) director Katie Peng sells 5,446 shares under 10b5-1 tax plan - Stock Titan
Mohammed Qatanani to sell 11,704 SRRK shares (NASDAQ: SRRK) - Stock Titan
SRRKScholar Rock Holding Corp Volatility & Greeks - Finviz
[144] Scholar Rock Holding Corp SEC Filing - Stock Titan
Form 144 Scholar Rock Holding Corp. For: 1 July By Investing.com - Investing.com India
SRRK (NASDAQ: SRRK) files Rule 144 notice to sell 5,446 shares via J.P. Morgan - Stock Titan
Pictet Asset Management Holding SA Cuts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Scholar Rock Holding Corp. Actuals & Estimates (NASDAQ:SRRK) - TradingView
Price to sales forward of Scholar Rock Holding Corp. – LSX:A2JMQW - TradingView
Price to earnings forward of Scholar Rock Holding Corp. – LSX:A2JMQW - TradingView
Enterprise value to revenue forward of Scholar Rock Holding Corp. – LSX:A2JMQW - TradingView
Scholar Rock Holding Corp. Actuals & Estimates (FWB:2QK) - TradingView
Enterprise value to EBITDA forward of Scholar Rock Holding Corp. – LSX:A2JMQW - TradingView
Enterprise value to EBIT forward of Scholar Rock Holding Corp. – LSX:A2JMQW - TradingView
Scholar Rock Holding Corp. Actuals & Estimates (BOATS:SRRK) - TradingView
2QK Forecast — Price Target — Prediction for 2027 - TradingView
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week HighWhat's Next? - MarketBeat
Scholar Rock Holding Corp stock hits 52-week high at 52.21 USD - Investing.com
Scholar Rock Holding eyes key EMA decision, shares trade higher on NASDAQ - AD HOC NEWS
Scholar Rock brings new apitegromab data to two rare muscle-disease meetings - Stock Titan
Scholar Rock Holding Corp (SRRK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):